On January 1, 2024, AlloVir Board Approved Reduction Its Workforce By Approximately 95% Of Current Employee Base To Reduce Costs And Preserve Capital - Filing
On January 1, 2024, AlloVir Board Approved Reduction Its Workforce By Approximately 95% Of Current Employee Base To Reduce Costs And Preserve Capital - Filing
The move follows AlloVir's announcement on December 22, 2023 that it is discontinuing its three global Phase 3 posoleucel studies. This workforce reduction will take place primarily during the first quarter of 2024 and expects to be substantially completed by April 15, 2024. As a result of these actions, AlloVir expects to incur personnel-related restructuring charges of approximately $13 million in connection with one-time employee termination cash expenditures, including severance and other benefits, which are expected to be substantially incurred in the first quarter of 2024.
此举是在AlloVir于2023年12月22日宣布停止其三项全球3期posoleucel研究之后采取的。裁员将主要在2024年第一季度进行，预计将在2024年4月15日之前基本完成。由于这些行动，AlloVir预计将产生约1300万美元的人事相关重组费用，这些费用与一次性员工解雇现金支出有关，包括遣散费和其他福利，预计这些支出将在2024年第一季度大量产生。